ストックスクリーナーアプリを入手
23.84
5.39%
1.22
前日終値:
$22.62
開ける：
$22.68
24時間の取引高:
545.29K
Relative Volume:
0.59
時価総額：
$1.52B
収益：
$13.05M
当期純損益:
$-60.54M
株価収益率:
-20.55
EPS:
-1.16
ネットキャッシュフロー:
$-37.82M
1週間 パフォーマンス:
-9.59%
1か月 パフォーマンス:
-17.96%
6か月 パフォーマンス:
-51.11%
1年 パフォーマンス:
-49.79%
1日の値動き範囲:
$22.52
$23.97
1週間の範囲:
$22.48
$28.13
52週間の値動き範囲:
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
23.84 | 1.52B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.05 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.98 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
557.00 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.85 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.99 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Bluefield Daily Telegraph
Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion - TipRanks
Trend Tracker for (JANX) - news.stocktradersdaily.com
Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com - Investing.com India
Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc - TipRanks
Janux Therapeutics price target lowered to $36 from $41 at Scotiabank - TipRanks
Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus
Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T - GuruFocus
Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position - TipRanks
Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight - GuruFocus
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace
Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback - TipRanks
Janux Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News - GuruFocus
Janux Therapeutics reports Q1 EPS (38c), consensus (39c) - TipRanks
BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.38 - TradingView
Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007 - TipRanks
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling - Defense World
Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation - TipRanks
Janux commences Phase Ib studies in trial for prostate cancer treatment - Yahoo
Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007 - TipRanks
Janux Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential - Insider Monkey
Janux Therapeutics begins phase 1b trial for prostate cancer therapy - Investing.com
Janux Therapeutics begins phase 1b trial for prostate cancer therapy By Investing.com - Investing.com India
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates - Business Wire
Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? - Insider Monkey
Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential - Insider Monkey
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
A new trading data show Janux Therapeutics Inc (JANX) is showing positive returns. - Sete News
Learn to Evaluate (JANX) using the Charts - news.stocktradersdaily.com
Trading Day Review: Janux Therapeutics Inc (JANX) Loses Momentum, Closing at 32.05 - DWinneX
Should Janux Therapeutics Inc (NASDAQ: JANX) Rally After -123.74% Drop From High? - Marketing Sentinel
Wells Fargo & Company MN Grows Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Are Janux Therapeutics Inc’shares a good deal? - uspostnews.com
Latest Insider moments: Meyer Andrew Hollman, Janux Therapeutics Inc [JANX] Chief Business Officer sold 3,334 shares – Knox Daily - knoxdaily.com
Russell Investments Group Ltd. Buys 442 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics Inc (JANX) Worth Considering For The Next Few Weeks - Stocksregister
Legal & General Group Plc Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - American Banking and Market News
LPL Financial LLC Makes New $439,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Financial Metrics Exploration: Understanding Heron Therapeutics Inc (HRTX) Through Ratios - DWinneX
Cerity Partners LLC Acquires Shares of 4,478 Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Astera Labs, Inc. (NASDAQ:ALAB) Given Average Recommendation of “Buy” by Analysts - Defense World
Janux Therapeutics Inc (JANX)’s stock chart: A technical perspective - uspostnews.com
Janux Therapeutics Inc [JANX] Shares Rise 5.36 % on Wednesday - knoxdaily.com
Oncology’s Most Eligible Unpartnered Assets - insights.citeline.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Invesco Ltd. - Defense World
Long Term Trading Analysis for (JANX) - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
JPMorgan Chase & Co. Boosts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
Janux Therapeutics Inc (JANX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
May 01 '25 |
Sale |
32.03 |
3,333 |
106,745 |
82,139 |
1.68%
大文字化:
|
ボリューム (24 時間):